Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, Taipei, Taiwan.
Gene'e Tech Co. Ltd., New Taipei City, Taiwan.
Int J Nanomedicine. 2020 Dec 18;15:10331-10347. doi: 10.2147/IJN.S281029. eCollection 2020.
Lung cancer is the leading cause of cancer patient death in the world. There are many treatment options for lung cancer, including surgery, radiation therapy, chemotherapy, targeted therapy, and combined therapy. Despite significant progress has been made in the diagnosis and treatment of lung cancer during the past few decades, the prognosis is still unsatisfactory.
To resolve the problem of chemotherapy failure, we developed a magnetite-based nanomedicine for chemotherapy acting synergistically with loco-regional hyperthermia.
The targeting carrier consisted of a complex of superparamagnetic iron oxide (SPIO) and poly(sodium styrene sulfonate) (PSS) at the core and a layer-by-layer shell with cisplatin (CDDP), together with methotrexate - human serum albumin conjugate (MTX-HSA conjugate) for lung cancer-specific targeting, referred to hereafter as SPIO@PSS/CDDP/HSA-MTX nanoparticles (NPs).
SPIO@PSS/CDDP/HSA-MTX NPs had good biocompatibility and stability in physiological solutions. Furthermore, SPIO@PSS/CDDP/HSA-MTX NPs exhibited a higher temperature increase rate than SPIO nanoparticles under irradiation by a radiofrequency (RF) generator. Therefore, SPIO@PSS/CDDP/HSA-MTX NPs could be used as a hyperthermia inducer under RF exposure after nanoparticles preferentially targeted and then accumulated at tumor sites. In addition, SPIO@PSS/CDDP/HSA-MTX NPs were developed to be used during combined chemotherapy and hyperthermia therapy, exhibiting a synergistic anticancer effect better than the effect of monotherapy.
Both in vitro and in vivo results suggest that the designed SPIO@PSS/CDDP/HSA-MTX NPs are a powerful candidate nanoplatform for future antitumor treatment strategies.
肺癌是全球癌症患者死亡的主要原因。肺癌有许多治疗选择，包括手术、放疗、化疗、靶向治疗和联合治疗。尽管在过去几十年中，肺癌的诊断和治疗取得了重大进展，但预后仍然不尽人意。
为了解决化疗失败的问题，我们开发了一种基于磁铁矿的纳米医学，用于与局部热疗协同作用的化疗。
靶向载体由超顺磁性氧化铁（SPIO）和聚（苯乙烯磺酸钠）（PSS）的复合物作为核心，以及具有顺铂（CDDP）的层层壳，以及甲氨蝶呤-人血清白蛋白缀合物（MTX-HSA 缀合物）用于肺癌特异性靶向，以下简称 SPIO@PSS/CDDP/HSA-MTX 纳米颗粒（NPs）。
SPIO@PSS/CDDP/HSA-MTX NPs 在生理溶液中具有良好的生物相容性和稳定性。此外，SPIO@PSS/CDDP/HSA-MTX NPs 在射频（RF）发生器照射下表现出比 SPIO 纳米颗粒更高的升温速率。因此，SPIO@PSS/CDDP/HSA-MTX NPs 可以在纳米颗粒优先靶向并在肿瘤部位积累后，在 RF 暴露下用作热疗诱导剂。此外，SPIO@PSS/CDDP/HSA-MTX NPs 被开发用于联合化疗和热疗治疗，表现出比单一疗法更好的协同抗癌作用。
体内外结果均表明，设计的 SPIO@PSS/CDDP/HSA-MTX NPs 是未来抗肿瘤治疗策略的有力候选纳米平台。
